As of 10:42 on April 24, 2025, the CSI Vaccine and Biotechnology Index rose by 0.36%, and its constituent stocks Rongchang Bio rose by 4.38%, Maiwei Bio rose by 4.27%, Qianhong Pharmaceutical rose by 3.47%, Hitech Bio rose by 2.89%, and North China Pharmaceutical rose by 2.33%. The Bio-Vaccine ETF (562860) is in a stalemate between long and short positions.

The Bio-Vaccine ETF closely tracks the CSI Vaccine and Biotechnology Index. The CSI Vaccine and Biotechnology Index selects no more than 50 listed companies whose businesses involve vaccine research and development, vaccine production, vaccine consumables, vaccine production equipment and other biotechnology fields as samples to reflect the overall performance of listed companies with vaccine and biotechnology themes.

Data shows that as of March 31, 2025, the top ten weighted stocks in the CSI Vaccine and Biotechnology Index are Zhifei Bio, Wantai Bio, Watson Bio, Hualan Bio, Kangtai Bio, BeiGene, Junshi Bio, Changchun High-Tech, Shandong YaoBo, and Fosun Pharma, accounting for a total of 49.93%.

In terms of news, Kangfang Bio's dual-antibody drug Ivosimab (PD-1/VEGF dual antibody) once again defeated PD-1 in a head-to-head trial. This time the challenge was BeiGene's tislelizumab combination therapy. The registration phase III clinical study (AK112-306/HARMONi-6) of Ivosimab combined with chemotherapy versus tislelizumab combined with chemotherapy as the first-line treatment for advanced squamous non-small cell lung cancer (sq-NSCLC) showed strong positive results in the head-to-head trial, and the research results showed statistically significant benefits and major clinical benefits.

https://finance.eastmoney.com/a/202504243387035410.html